For adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. See FULL INDICATION »

I’M IN for the next adventure

HOW WAS IMFINZI STUDIED IN PEOPLE WITH PREVIOUSLY UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)?

IMFINZI was studied in a clinical trial that included people diagnosed with ES-SCLC who had not yet undergone treatment.

268 people given IMFINZI + chemotherapy

268

people were given
IMFINZI + chemotherapy

AND

269 people were given only chemotherapy

269

people were given only chemotherapy

Everyone in the clinical trial received the standard treatment for previously untreated ES-SCLC, which included a combination of 2 types of chemotherapy:

Chemotherapy treatment iconetoposide

Chemotherapy treatment iconcarboplatin or cisplatin

IMFINZI + CHEMOTHERAPY HELPED PEOPLE LIVE LONGER COMPARED TO CHEMOTHERAPY ALONE

The trial measured how long people with ES-SCLC lived while taking IMFINZI + chemotherapy. In studies of treatments for cancer, this is called "overall survival." It is measured in months.

Median Overall Survival*

People treated with IMFINZI + chemotherapy were alive at 13 months

13 MONTHS on IMFINZI + chemotherapy

People given chemotherapy alone were alive at 10.3 months

10.3 MONTHS on chemotherapy alone

People taking IMFINZI + chemotherapy had a 27% lower risk of dying compared to those taking chemotherapy alone.

*Median overall survival is the length of time that half the people are living. Median is the middle number in a group of numbers arranged from lowest to highest.

RESULTS WITH IMFINZI OVER 3 YEARS

Over the course of 3 years, follow-up analyses measured the number of people who were living taking IMFINZI + chemotherapy compared to chemotherapy alone.

At 1 year†:

  • 52.8% on IMFINZI + chemotherapy
  • 39.3% on chemotherapy alone

At 2 years†:

  • 22.9% on IMFINZI + chemotherapy
  • 13.9% on chemotherapy alone
Chemotherapy treatment icon

In a follow-up analysis at 3 years,† 17.6% of the people who received IMFINZI + chemotherapy were living compared with 5.8% on chemotherapy alone.

†From a follow-up analysis. Based on the limitations of these follow-up analyses, results are descriptive only and your experience may differ.

PEOPLE WHO WERE LIVING WITHOUT THEIR CANCER SPREADING OR GROWING‡

A follow-up analysis from the study measured the amount of people who lived without their tumors growing or spreading while treated with IMFINZI + chemotherapy or chemotherapy alone.

At 1 year§:

18%

of people
treated with IMFINZI + chemotherapy

18%

of people
treated with IMFINZI + chemotherapy

5%

of people
treated with chemotherapy alone

5%

of people
treated with chemotherapy alone

In a follow-up analysis at 2 years§:

11%

of people
treated with IMFINZI + chemotherapy

11%

of people
treated with IMFINZI + chemotherapy

3%

of people
treated with chemotherapy alone

3%

of people
treated with chemotherapy alone

In the clinical trial, half of the people lived without their tumors growing or spreading for 5.1 months when treated with IMFINZI + chemotherapy and 5.4 months when treated with chemotherapy alone.

‡Based on the limitations of these analyses, results are descriptive only and your experience may differ.

§From a follow-up analysis. Based on the limitations of this analysis, results are descriptive only and your experience may differ. Numbers are rounded to the nearest whole percentage.

PEOPLE WHO SAW THEIR TUMORS SHRINK

7 out of 10 people on IMFINZI + chemotherapy saw their tumors shrink

068%

of people treated with IMFINZI + chemotherapy

6 out of 10 people on chemotherapy alone saw their tumors shrink

058%

of people treated with chemotherapy alone

Please keep in mind that not everyone may experience the same results.

Patient starter kit icon

Get more information and resources for starting IMFINZI

SIGN UP FOR MORE SUPPORT

NEXT: What to expect with IMFINZI

Important Safety Information

What is the most important information I should know about IMFINZI?

IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

What is IMFINZI?IMFINZI® (durvalumab) SCLC page logo

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).

It is not known if IMFINZI is safe and effective in children.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

  • Lung problems: cough, shortness of breath, and chest pain

  • Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness

  • Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), and bleeding or bruising more easily than normal

  • Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; and changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

  • Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, and loss of appetite

  • Skin problems icon

    Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; and swollen lymph nodes

  • Pancreas problems: pain in your upper stomach area (abdomen), severe nausea or vomiting, and loss of appetite

  • Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with IMFINZI. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: Chest pain, irregular heartbeats, shortness of breath or swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling, numbness or weakness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eye sight; persistent or severe muscle pain or weakness, muscle cramps, joint pain, joint stiffness or swelling; and low red blood cells and bruising

  • Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, and back or neck pain

  • Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with IMFINZI. Your healthcare provider will monitor you for these complications

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects.

Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you:

  • have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
  • have received an organ transplant
  • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
  • have received radiation treatment to your chest area
  • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • are pregnant or plan to become pregnant. IMFINZI can harm your unborn baby

    • Females who are able to become pregnant:

    • Your healthcare provider will give you a pregnancy test before you start treatment with IMFINZI.
    • You should use an effective method of birth control during your treatment and for 3 months after the last dose of IMFINZI. Talk to your healthcare provider about birth control methods that you can use during this time.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with IMFINZI.
  • are breastfeeding or plan to breastfeed. It is not known if IMFINZI passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of IMFINZI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMFINZI?

IMFINZI can cause serious side effects (see above):

The most common side effects of IMFINZI when used with other anticancer medicines in people with ES-SCLC include nausea, hair loss, and feeling tired or weak.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products.Report side effects related to AstraZeneca products If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products.Report side effects related to AstraZeneca products If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

What is IMFINZI?IMFINZI® (durvalumab) SCLC page logo

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).

It is not known if IMFINZI is safe and effective in children.

Please see Full Prescribing Information including Medication Guide for IMFINZI.

+

Important Safety Information +

What is the most important information I should know about IMFINZI?

IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

What is IMFINZI?IMFINZI® (durvalumab) SCLC page logo

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).

It is not known if IMFINZI is safe and effective in children.